Skip to content

De SPECTACLE studie

Correlation between speckle tracking determined left atrial strain measurements and voltage mapping in patients with paroxysmal atrial fibrillation undergoing catheter ablation: the SPECTACLE study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29521
Enrollment
50
Registered
2015-04-21
Start date
2015-06-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Measurement of left atrial voltage and echocardiographic strain measurements

Sponsors

MST Enschede
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Eligible to undergo percutaneous radiofrequent catheter ablation of atrial fibrillation. -Sinus rhythm during echocardiography -Age >18 years -Expected follow up >12 months

Exclusion criteria

Exclusion criteria: -Previous PVI or MAZE procedure. -Emphysema -Unable to provide informed consent. -Pregnancy -Presence of pacemaker or ICD

Design outcomes

Primary

MeasureTime frame
Correlation between speckle tracking determined global strain measurement and percentage of low voltage points in the left atrium.

Secondary

MeasureTime frame
-Recurrence of atrial fibrillation within 12 months after a blanking period of 3 months defined as registration of atrial fibrillation on ECG or episode lasting >30 seconds on Holter/Vitaphone recording. -Correlation between strain/strain rate measurements and regional percentage of low voltage in the LA.; -Correlation between laboratory values and voltage measurements -Predictive value of strain/strain rate measurements and low voltage percentage for recurrent atrial fibrillation after catheter ablation. -Quality of life before and after PVI measured with SF-12 questionnaire

Contacts

Public ContactT. Hesselink

Medisch Spectrum Twente

t.hesselink@mst.nltel. (053) 487 2110

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)